Rhumbline Advisers Boosts Holdings in BioScrip, Inc. (BIOS)

Rhumbline Advisers raised its position in BioScrip, Inc. (NASDAQ:BIOS) by 9.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 130,122 shares of the company’s stock after purchasing an additional 10,985 shares during the period. Rhumbline Advisers owned about 0.11% of BioScrip worth $353,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of BIOS. Gilder Gagnon Howe & Co. LLC grew its holdings in BioScrip by 248.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock valued at $41,298,000 after purchasing an additional 10,845,410 shares during the last quarter. FMR LLC grew its holdings in BioScrip by 36.1% in the first quarter. FMR LLC now owns 4,803,000 shares of the company’s stock valued at $8,165,000 after purchasing an additional 1,273,205 shares during the last quarter. California Public Employees Retirement System grew its holdings in BioScrip by 37.5% in the first quarter. California Public Employees Retirement System now owns 663,700 shares of the company’s stock valued at $1,128,000 after purchasing an additional 181,000 shares during the last quarter. Roanoke Asset Management Corp NY grew its holdings in BioScrip by 72.9% in the second quarter. Roanoke Asset Management Corp NY now owns 403,280 shares of the company’s stock valued at $1,095,000 after purchasing an additional 170,000 shares during the last quarter. Finally, KCG Holdings Inc. grew its holdings in BioScrip by 176.2% in the first quarter. KCG Holdings Inc. now owns 209,586 shares of the company’s stock valued at $356,000 after purchasing an additional 133,715 shares during the last quarter. 84.77% of the stock is currently owned by institutional investors.

Shares of BioScrip, Inc. (NASDAQ:BIOS) opened at 2.90 on Monday. The firm’s market cap is $369.68 million. The company’s 50 day moving average price is $2.78 and its 200-day moving average price is $2.34. BioScrip, Inc. has a 1-year low of $0.98 and a 1-year high of $3.39.

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.01). The firm had revenue of $218.11 million during the quarter, compared to the consensus estimate of $220.05 million. The business’s quarterly revenue was down 6.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.14) earnings per share. Equities analysts expect that BioScrip, Inc. will post ($0.55) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/10/09/rhumbline-advisers-boosts-holdings-in-bioscrip-inc-bios.html.

In other news, Director Michael G. Bronfein sold 27,000 shares of the business’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $2.69, for a total transaction of $72,630.00. Following the sale, the director now directly owns 129,669 shares of the company’s stock, valued at $348,809.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Coliseum Capital Management, L sold 886,478 shares of the business’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $3.08, for a total value of $2,730,352.24. The disclosure for this sale can be found here. Insiders have sold 3,760,419 shares of company stock worth $11,144,519 over the last ninety days. 0.80% of the stock is owned by insiders.

Several research firms have weighed in on BIOS. ValuEngine raised BioScrip from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Zacks Investment Research lowered BioScrip from a “buy” rating to a “hold” rating in a report on Monday, August 14th. BidaskClub lowered BioScrip from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. SunTrust Banks, Inc. raised BioScrip from a “hold” rating to a “buy” rating and upped their target price for the company from $3.25 to $3.75 in a report on Thursday, August 10th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $4.00 target price (up previously from $3.00) on shares of BioScrip in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. BioScrip presently has a consensus rating of “Hold” and a consensus target price of $3.75.

BioScrip Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip, Inc. (NASDAQ:BIOS).

Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply